Who makes First-Line Dara-BorCyD Treatment?

First-Line Dara-BorCyD Treatment is developed by Peking University First Hospital.

What development phase is First-Line Dara-BorCyD Treatment in?

First-Line Dara-BorCyD Treatment is in Phase 1.

Last reviewed 2026-05-14 · How we verify

First-Line Dara-BorCyD Treatment

Peking University First Hospital · Phase 1 active Small molecule Quality 3/100

At a glance

Generic name	First-Line Dara-BorCyD Treatment
Sponsor	Peking University First Hospital
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

First-Line Dara-BorCyD Treatment CI brief — competitive landscape report
First-Line Dara-BorCyD Treatment updates RSS · CI watch RSS
Peking University First Hospital portfolio CI